Following Poor Clinical Trial Outcomes, Concert Pharmaceuticals Discontinues Schizophrenia Drug Development

Concert Pharmaceutical discontinued development of its adjunctive treatment for schizophrenia, CTP-692 (D-serine) after it failed to meet its primary endpoint and other secondary endpoints in a Phase II trial. The trial was a double-blind, randomized, placebo-controlled study to evaluate safety and efficacy of CTP-692. The primary endpoint was change in the Positive and Negative Syndrome Scale (PANSS) total score at 12 weeks compared to baseline.

The 325 participants in the clinical trial were already on a stable course of an antipsychotic medication. They were randomized to receive 1, 2 or 4-gram doses of CTP . . .